4575 Share Price Performance
JP¥845.00
-245.00 (-22.48%)
Price JP¥845.00
Share Pricen/a
No recently updated narratives available.
CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.